BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17229831)

  • 1. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp.
    Woodford N; Hill RL; Livermore DM
    J Antimicrob Chemother; 2007 Mar; 59(3):582-3. PubMed ID: 17229831
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.
    Cui JC; Liu YN; Chen LA
    J Antibiot (Tokyo); 2010 Jan; 63(1):29-31. PubMed ID: 19911030
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
    Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
    Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea.
    Park YK; Choi JY; Song JH; Ko KS
    Int J Antimicrob Agents; 2009 Mar; 33(3):289-90. PubMed ID: 19091518
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde AM; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    J Antimicrob Chemother; 2017 May; 72(5):1359-1363. PubMed ID: 28108677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
    Casal M; Rodríguez F; Johnson B; Garduno E; Tubau F; de Lejarazu RO; Tenorio A; Giménez MJ; Bartolomé R; Garcia-Rey C; Aguilar L; García-Escribano N
    J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.
    Betts JW; Phee LM; Hornsey M; Woodford N; Wareham DW
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3541-6. PubMed ID: 24687491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.
    Hanberger H; Burman LG; Cars O; Erlandsson M; Gill H; Nilsson LE; Nordlinder D; Walther SM;
    Acta Anaesthesiol Scand; 2007 Aug; 51(7):937-41. PubMed ID: 17635399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline minimum inhibitory concentration for carbapenem-resistant Acinetobacter baumannii by two methods.
    Wang R; Wang H; She D
    Chin Med J (Engl); 2014; 127(10):1997. PubMed ID: 24824274
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates.
    Zhang Y; Li P; Yin Y; Li F; Zhang Q
    J Antibiot (Tokyo); 2017 Feb; 70(2):193-195. PubMed ID: 27460764
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of tigecycline and other tetracyclines against carbapenem-resistant Acinetobacter species: report from a tertiary care centre in Karachi, Pakistan.
    Shakoor S; Khan E; Zafar A; Hasan R
    Chemotherapy; 2010; 56(3):184-9. PubMed ID: 20551633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.